Why has the Telix Pharmaceuticals share price rocketed 53% in a month?
ASX 200 healthcare share Telix Pharmaceuticals Ltd (ASX: TLX) has had a stellar month. Here are all the details.
Source: fool.com.au
📰 Michael Wheatcroft News
Michael Wheatcroft News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Michael Wheatcroft. Real-time updates on events, politics, business and more.
Telix Pharmaceuticals Limited: Telix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of Dedicaid
MELBOURNE, Australia, April 26, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the expansion of its artificial intelligence (AI) capability
Source: finanznachrichten.de
Telix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of Dedicaid
MELBOURNE, Australia, April 27, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the expansion of its...
Source: fnarena.com
Telix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of Dedicaid
/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the expansion of its artificial intelligence (AI) capability with...
Source: prnewswire.com
Telix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of Dedicaid
/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the expansion of its artificial intelligence (AI) capability with...
Source: prnewswire.com
Telix Pharmaceuticals Limited: Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical
MELBOURNE, Australia, April 16, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces successful preclinical development of radiolabelled olaratumab
Source: finanznachrichten.de
Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical
MELBOURNE, Australia, April 17, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces successful preclinical development of radiolabelled olaratumab, an antibody licensed from Eli Lilly and Company (Lilly). Telix has demonstrated proof-of-concept (PoC) of using olaratumab to selectively deliver both diagnostic and therapeutic radiation to tumours as a radiopharmaceutical moiety and has produced a candidate for clinical translation. Telix will now progre...
Source: singaporestar.com
Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical
/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces successful preclinical development of radiolabelled olaratumab, an...
Source: prnewswire.com
Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical
/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces successful preclinical development of radiolabelled olaratumab, an...
United States United Kingdom Eli Lilly Kyahn Williamson Michael Wheatcroft Australian Therapeutic Goods Administration
Source: prnewswire.com
Telix and UniQuest to Collaborate on Radiolabelled Immune Targeting Peptide
MELBOURNE, Australia, Oct. 27, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a collaboration with UniQuest...
Source: fnarena.com